TNF and inflammatory bowel disease: POTENTIAL SOLUTIONS: The expert panel notes that insufficient patient understanding, trust, and acceptance of biosimilar medicines remains a highly influential barrier to improving biosimilar anti-TNF-α use and early treatment intervention in IBD.